An, Lihong
Lin, Yuehui
Deng, Biping
Yin, Zhichao
Zhao, Defeng
Ling, Zhuojun
Wu, Tong
Zhao, Yongqiang
Chang, Alex H.
Tong, Chunrong
Liu, Shuangyou http://orcid.org/0000-0001-9982-7099
Article History
Received: 23 January 2022
Accepted: 4 April 2022
First Online: 12 April 2022
Declarations
:
: This phase I study was approved by Beijing Boren Hospital ethics committee and registered on Chinese Clinical Trial Registry/WHO International Clinical Trial Registry (ClinicalTrials#: ChiCTR1900024456), written informed consents were obtained in accordance with the Declaration of Helsinki, for children under 18 years old, the participant consent form was signed by their parent/legal guardian.
: Alex H. Chang is a founding member of Shanghai YaKe Biotechnology Ltd., a biotechnology company focused on research and development of tumor cellular immunotherapy. The remaining authors have no conflicts of interest.